Close Menu

NEW YORK (GenomeWeb) – The US Food and Drug Administration has expanded the intended use for Dako's PD-L1 IHC 28-8 pharmDx as a complementary diagnostic to assess the magnitude of benefit melanoma patients might derive from the immunotherapeutic Opdivo (nivolumab), the Agilent subsidiary announced today.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.


This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients.